|
|
|
07.04.26 - 05:31
|
Krankenkassen: ′Lieber etwas teureres Bier und Zigaretten′ (DPA-AFX)
|
|
|
BERLIN (dpa-AFX) - Höhere Steuern auf Tabak und Alkohol wären aus Sicht der Krankenkassen sinnvoll. "Lieber etwas teureres Bier und Zigaretten als die milliardenteuren Folgeerkrankungen vom Trinken und Rauchen", sagte der Chef des GKV-Spitzenverbands, ......
|
|
|
|
|
|
|
07.04.26 - 02:06
|
Stricter Chinese scrutiny of offshore vehicles a blow for tech and biotech IPO candidates (SCMP)
|
|
|
US dollar-denominated funds could face more hurdles when investing in Chinese tech and biotech companies as Beijing adopts a stricter approach to companies seeking listings via offshore incorporated vehicles.
Indicative of Chinese regulators' caution in overseeing sensitive industries, industry sources say the move ensures that any sale of assets does not escape regulatory scrutiny.
And for any offshore incorporated structures that are approved, the stock regulator requires listing applicants to......
|
|
|
06.04.26 - 22:15
|
Wie Franklin Biotech-Chancen gezielt nutzt (Fundresearch)
|
|
|
Mit einem klar strukturierten Bottom-up-Ansatz und tiefgehender wissenschaftlicher Analyse identifiziert Fondsmanager Evan McCulloch im Franklin Biotechnology Discovery Fund gezielt unterbewertete Biotech-Unternehmen. In einem Markt, der von Innovationsschüben, M&A-Dynamik und Bewertungsunterschieden geprägt ist, setzt der Fonds auf eine ausgewogene Mischung aus wachstumsstarken Small Caps und stabilen Large Caps – und eröffnet Anlegern so attraktive Chancen im globalen Biotechnologiesektor....
|
|
|
06.04.26 - 21:21
|
Big Pharma Forced To Yank COVID Vaxx Study Due To Lack Of Participants (ZeroHedge)
|
|
|
Big Pharma Forced To Yank COVID Vaxx Study Due To Lack Of Participants
Authored by Ben Sellers via Headline USA,
Two of the major pharmaceutical companies connected with the controversial COVID vaccines were forced to abandon a new research study after failing to garner enough participants.
Pfizer and German vax maker BioNTech had sought to research an updated version of the vaccine in adults ages 50 to 64, but were unable to generate the data needed due to the low enrollment in the trials, Reuters reported.
The study was needed in order to meet new guidelines imposed by the Food and Drug Administration that require the pharmaceutical companies to provide data on the efficacy of the vaccine in comparison with a placebo.
However, it marks a peculiar coda to the pandemic era, when mass formation psychosis swept the globe forcing individuals to forgo their civil liberties en masse and to inject the experimental, gene-altering serum into their DNA under extreme social duress.
Since ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
05.04.26 - 01:21
|
Less Than Half Of Health Care Workers Received An Updated COVID-19 Vaccine: CDC (ZeroHedge)
|
|
|
Less Than Half Of Health Care Workers Received An Updated COVID-19 Vaccine: CDC
Authored by Zachary Stieber via The Epoch Times,
A minority of health care workers received an updated COVID-19 vaccine, according to a newly reported survey from the Centers for Disease Control and Prevention.
Just 40.2 percent of health care personnel who responded to the survey said they received a COVID-19 shot between the fall of 2024 and early 2025, CDC researchers said on April 2.
The rate of vaccination was higher, 76.3 percent, for influenza.
The survey was conducted online from March 26 to April 17 in 2025, following the 2024–2025 respiratory virus season. The season begins in the fall of each year and runs into the next year.
Some 2,650 health care workers responded to the survey.
At the time, the CDC recommended influenza and COVID-19 vaccination for virtually all Americans aged 6 months and older, regardless of the number of prior doses. The CDC more recently narrowed its recommendations for those sh...
|
|
|
04.04.26 - 19:00
|
India′s pharma exports rise 5.6% to $28.29 billion till Feb in FY26 (Times of India)
|
|
|
India's pharmaceutical exports are thriving, reaching $28.29 billion in April-February FY26, a 5.6% rise despite global challenges. The sector, currently valued at $60 billion, is projected to hit $130 billion by 2030. Leaders are optimistic about continued growth, even with potential US tariff impacts on future exports....
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
